Significant advances in understanding the signaling pathways that drive pulmonary fibrosis (PF) are reshaping how clinicians diagnose and treat idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

As multiple late-stage trials report in 2025–2026, education is critical to equip clinicians with the knowledge and frameworks to integrate biologics into personalized COPD management.

Join expert faculty to discuss the latest in COPD management!